In the recent published APHINITY trial, the dual anti‐HER2 with trastusumab and pertusumab could improve 5‐year OS to near 98%.28 Another trial also proved taxanes with trastusumab could be an optimal option for small HER2+ tumor with 3‐year rate of survival free from invasive disease was 98.7%.29 All the above information implied a de‐escalating strategy for the management of T1a and T1b HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.